Lilly's Connelly blasts reps mouthing off online

Share this article:

Lilly USA president Deirdre Connelly yesterday took a swipe at online forums that attract disgruntled, venting sales reps, describing sites like as “outlets for people who don't have the courage to speak out with their ideas” for improving their roles and the performance of their companies.

Connelly was addressing delegates at Pharmaceutical Executive's Marketing & Sales Summit in Philadelphia on the reevaluation and restructure of Lilly's sales operation. With the company already in the second year of a five-year plan, Connelly emphasized the need for sales reps to make a transition from merely delivering messages in the physician's office to actually solving problems for the physician.

“We need to have an expanded view of what sales training looks like, but without losing our focus,” she said. “You need to be certain that what you do is relevant.”

One approach Lilly will take is to build its specialty sales forces from within the organization. “On average, those reps promoted from primary care to specialty fields do better than those hired from the outside,” Connelly noted.

But while Connelly leveled charges of cowardice to the outspoken Web community, she is not lacking in courage herself. Connelly, once a rep in the 1980s, likes to go undercover every so often as a Lilly rep, just to keep her finger on the pulse of detailing. On a recent mission in northern Indianapolis, she described how one particular doctor walked past and ignored her three times before finally returning with pen, expecting to sign for samples.

When Connelly told the physician that she didn't have samples but just wanted to talk for a minute, he stepped back, seemingly offended, and asked her why she was there and where was his regular rep? Eventually, he asked to see Connelly's business card. “President, Lilly USA,” he read. “President? President of what?”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...